Literature DB >> 24125563

A rare association of early-onset inclusion body myositis, rheumatoid arthritis and autoimmune thyroiditis: a case report and literature review.

A M Clerici, G Bono, M L Delodovici, G Azan, G Cafasso, G Micieli.   

Abstract

Sporadic inclusion body myositis (sIBM) is a slowly progressive, red-rimmed vacuolar myopathy leading to muscular atrophy and progressive weakness; it predominantly affects males older than fifty years, and is resistant to immunotherapy. It has been described in association with immuno-mediated thrombocytopenic purpura, multiple sclerosis, connective tissue disorders and, occasionally, rheumatoid arthritis. A 37-year-old man with longstanding rheumatoid arthritis and autoimmune thyroiditis with hypothyroidism was referred to us with slowly progressive, diffuse muscle weakness and wasting, which had initially involved the volar finger flexors, and subsequently also the ankle dorsiflexors and knee extensors. Needle electromyography showed typical myopathic motor unit potentials, fibrillation and positive sharp waves with normal nerve conduction studies. Quadriceps muscle biopsy was suggestive of sIBM. Considering data published in the literature, this case may be classified as an early-onset form. The patient was treated with long-term intravenous immunoglobulin and obtained a substantial stabilization of his muscle strength.

Entities:  

Mesh:

Year:  2013        PMID: 24125563      PMCID: PMC3812730          DOI: 10.11138/FNeur/2013.28.2.127

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  31 in total

1.  A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.

Authors:  M C Dalakas; B Koffman; M Fujii; S Spector; K Sivakumar; E Cupler
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

2.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

Authors:  F I MAHONEY; D W BARTHEL
Journal:  Md State Med J       Date:  1965-02

Review 3.  Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches.

Authors:  Merrilee Needham; Frank L Mastaglia
Journal:  Lancet Neurol       Date:  2007-07       Impact factor: 44.182

4.  Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy.

Authors:  S Carpenter; G Karpati; I Heller; A Eisen
Journal:  Neurology       Date:  1978-01       Impact factor: 9.910

5.  Inclusion body myositis.

Authors:  E J Yunis; F J Samaha
Journal:  Lab Invest       Date:  1971-09       Impact factor: 5.662

6.  Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study.

Authors:  M C Dalakas; B Sonies; J Dambrosia; E Sekul; E Cupler; K Sivakumar
Journal:  Neurology       Date:  1997-03       Impact factor: 9.910

7.  Inclusion body myositis in association with rheumatoid arthritis.

Authors:  M Soden; K Boundy; D Burrow; P Blumbergs; M Ahern
Journal:  J Rheumatol       Date:  1994-02       Impact factor: 4.666

Review 8.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 9.  [Inclusion body myositis associated with chronic thyroiditis, Sjögren's syndrome and autoimmune cholangitis].

Authors:  Kiwa Hama; Hideto Miwa; Ichizo Nishino; Ikuya Nonaka; Tomoyoshi Kondo
Journal:  No To Shinkei       Date:  2004-06

10.  Inclusion body myositis: treatment with intravenous immunoglobulin.

Authors:  A A Amato; R J Barohn; C E Jackson; E J Pappert; Z Sahenk; J T Kissel
Journal:  Neurology       Date:  1994-08       Impact factor: 9.910

View more
  2 in total

1.  Multicenter reproducibility study of diffusion MRI and fiber tractography of the lumbosacral nerves.

Authors:  Wieke Haakma; Jeroen Hendrikse; Lars Uhrenholt; Alexander Leemans; Lene Warner Thorup Boel; Michael Pedersen; Martijn Froeling
Journal:  J Magn Reson Imaging       Date:  2018-02-09       Impact factor: 4.813

Review 2.  Idiopathic inflammatory myopathies overlapping with systemic diseases.

Authors:  Sébastien Lepreux; Johannes A Hainfellner; Anne Vital
Journal:  Clin Neuropathol       Date:  2018 Jan/Feb       Impact factor: 1.368

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.